Abstract: TH-PO207
Outcomes with Inpatient Use of Midodrine in Patients on Maintenance Hemodialysis with Heart Failure
Session Information
- Hypertension and CVD: Clinical - I
November 02, 2023 | Location: Exhibit Hall, Pennsylvania Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Hypertension and CVD
- 1602 Hypertension and CVD: Clinical
Authors
- Patel, Neev, LSU Health Shreveport, Shreveport, Louisiana, United States
- Alvarez Concejo, Bruno, LSU Health Shreveport, Shreveport, Louisiana, United States
- Mishra, Meenakshi, Ochsner Center for Academic Excellence, New Orleans, Louisiana, United States
- Lo, Kevin Bryan, Albert Einstein Medical Center, Philadelphia, Pennsylvania, United States
- Sequeira, Adrian P., LSU Health Shreveport, Shreveport, Louisiana, United States
- Kattubadi, Ayeesha, LSU Health Shreveport, Shreveport, Louisiana, United States
- Rangaswami, Janani, The George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, United States
Background
Midodrine, a peripheral vasoconstrictor, is commonly used in kidney failure patients for predialytic and intradialytic hypotension. However, in patients with systolic and/or right heart failure (HF), midodrine is potentially harmful. No known studies examine the safety of midodrine in hospitalized patients with kidney failure and HF.
Methods
We queried TriNetX database for inpatients with kidney failure and systolic and/or right HF who had at least an event of hypotension (SBP < 110 mm Hg or MAP < 70 mm Hg). Patients requiring critical care, inotropes or vasopressors were excluded. Cohorts were separated based on midodrine use. Temporality was established between hypotension, midodrine use, and hemodialysis, as shown in figure. Cohorts were matched for relevant comorbidities.
Results
In patients receiving midodrine, 6-month mortality risk ratio (RR) was significantly higher than no midodrine use (RR 1.53, 95% CI 1.037 to 2.246). Kaplan Meier survival analysis log-rank test at 6 months revealed a Hazard Ratio of 1.54 (95% CI 1.022 to 2.317).
Conclusion
In patients with systolic and/or right HF and kidney failure, hypotension is a limiting factor for decongestion and guideline directed therapy implementation, making midodrine a tool used in real world practice for stabilization. Our exploratory results in noncritically ill inpatients show an association between use of midodrine and higher 6-month mortality. This may reflect deleterious effects from vasoconstriction and/or unmeasured confounders in sicker patients with HF and kidney failure that increase mortality risk.
This study has multiple limitations. Given its observational nature, it cannot establish a cause-effect relationship. Other limitations include the lack of data regarding dosage and duration of midodrine, and severity and etiology of heart failure.
Our study demonstrates increased mortality associated with midodrine use for hypotension, warranting further research and consideration of alternative strategies.
Methods